Endocrine resistance in breast cancer: gene expression profiling and modifications of the estrogen receptor
Kok, M-R.

Citation for published version (APA):
List of publications

In preparation

In preparation

Submitted

Under review

Under review


Microarray based determination of ER, PR and HER2 receptor status n breast cancer.

J Pathol. 2009; 218(3): 316-26

J Pathol. 2009; 217(3): 372-9

Continued on next page...
List of publications

Continued from previous page...


_Breast Cancer Res Treat._ 2009; 113(2): 275-83


_Breast Cancer Research_ 2008; 10(6): R93

Kok M, Linn SC, Van de Vijver MJ. Estrogen receptor phenotypes defined by gene expression profiling. 


White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, Winter C, Gregory CG, Hogarty MD, Maris JM, Brodeur GM. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. 

_Oncogene_ 2005; 24(16): 2684-94

Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. 

_Oncogene_ 2003; 22(7): 1002-11

Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin’s lymphoma. 

_Tumoriology_ 2003; 24: 53-60

230